Exploring equitable treatment options for pediatric patients with sickle cell disease

Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.

Tracing how the infant brain responds to touch with near-infrared spectroscopy

Researchers from Tokyo Metropolitan University have measured how oxygenated hemoglobin levels in the blood change in infants’ brains in response to touch. Using spectroscopy methods with external sensors placed on the scalp of sleeping infants, they found that the time at which levels peak doesn’t change with infant age, but the amount by which it varies over time does. Insights like this shed light on how the physiology of infants develops.

Dodia calls for harmonisation of mining policies

By Millennium Reporter

THE Private Sector Development Association (PSDA) says there is need to harmonise the government mining policies and those of the foreign mining companies to ensure that both sides benefit unlike the current situation.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.


A new mechanism by which rotavirus makes you sick

Rotavirus causes gastroenteritis, a condition that includes diarrhea, deficient nutrient absorption and weight loss. Severe cases result in approximately 128,000 deaths annually in infants and children worldwide. Despite intense research on how rotavirus causes diarrhea, there is still no complete answer, but in this new study researchers at Baylor College of Medicine report a new mechanism by which rotavirus induces diarrhea, interfering with the normal absorption of nutrients in the intestine.

Novel combination therapy found to significantly reduce spleen volume in patients with myelofibrosis

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens—a major indicator of clinical improvement—compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.